{"filings":[{"id":1967559,"accession_number":"0001193125-26-326083","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2026-07-30T20:01:15+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI Q2 revenue $382.5M (+22% YoY); raises FY2026 guidance to $1.595-1.605B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $382.5M, up 22% YoY; GAAP net income $5.6M vs loss $42.8M in Q2 2025.","Adjusted EBITDA $8.0M vs -$5.6M; FY2026 revenue guidance raised to $1.595-1.605B.","Signed ~$200M in new Data and Applications licenses; MRD volume 9,000 tests.","Agreed to acquire Personalis for $16.25/share (~$1.5B enterprise value).","FDA approved xT Tumor Only CDx assay; first lab with both tumor-only and tumor-normal CDx."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1750517,"accession_number":"0001193125-26-309073","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2026-07-20T21:15:12+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tempus AI to acquire Personalis for $16.25/share; stock/cash mix; exchange ratio tied to TEM price","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Per share consideration: $16.25 cash or stock based on exchange ratio; Tempus may elect cash for up to 50% of shares.","Exchange ratio fixed at 0.3356 if TEM stock price ≤ $48.42; otherwise $16.25 / TEM 15-day VWAP.","Termination fee ~$76.8M payable by Personalis in certain circumstances; reverse termination fee same amount payable by Tempus.","Conditions: Personalis stockholder approval, HSR clearance, Nasdaq listing, tax opinion, no material adverse effect.","Personalis in-the-money options and RSUs converted to Tempus stock; out-of-the-money options cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1731196,"accession_number":"0001193125-26-308469","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2026-07-20T13:03:42+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tempus AI to acquire Personalis for $1.5B, adding MRD technology to precision oncology platform","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total enterprise value of $1.5B net of Tempus' existing stake; $16.25 per share in stock, with Tempus option to pay up to 50% cash.","Premium of 6% to Friday's close and 28% to 30-day VWAP; floating exchange ratio capped at 0.3356 Tempus shares per Personalis share.","Closing expected late 2026 or early 2027, subject to Personalis shareholder approval, regulatory clearances, and customary conditions.","Personalis reported Q2 preliminary revenue of $22.4M and 10,384 clinical tests, a 33% sequential increase in test volumes.","Acquisition expands Tempus' reach in the $20B MRD market, combining Personalis' NeXT Personal test with Tempus' AI platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609117,"accession_number":"0001193125-26-236814","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2026-05-22T20:01:21+00:00","items":["5.07"],"status":"ready","headline":"Tempus AI shareholders elect all nine directors, ratify PwC, approve triennial say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; highest votes for Eric D. Belcher with 234,038,276 for, 1,072,748 withheld.","Ratification of PricewaterhouseCoopers as auditor for FY2026: 262,396,207 for, 90,662 against, 65,045 abstain.","Advisory vote on say-on-pay frequency: 191,972,032 for three years, 42,744,443 for one year; Board adopts triennial cycle.","Broker non-votes of 27,440,890 on director elections and frequency vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49445,"accession_number":"0001193125-26-220115","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2026-05-12T23:18:38+00:00","items":["1.01","1.02","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Tempus AI closes $460M 0% convertible notes due 2032; repays $307.7M credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $460M aggregate principal of 0.00% Convertible Senior Notes due 2032, conversion price ~$69.26/share.","Net proceeds of ~$441.9M; used $307.7M to repay outstanding loans under senior secured credit facilities.","Paid ~$31.2M for capped call transactions to reduce potential dilution upon conversion.","Conversion rate initially 14.4388 shares per $1,000; notes redeemable at par after May 21, 2029 under conditions.","Credit Agreement with Ares Capital terminated upon repayment in full on May 12, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94944,"accession_number":"0001193125-26-206317","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI Q1 revenue $348M (+36% YoY); raises FY2026 guidance to $1.59-1.60B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $348.1M, +36% YoY; Diagnostics $261.1M (+34.7%), Data & Apps $87.0M (+40.5%).","Net loss $(125.9)M vs $(68.0)M YoY, includes $56.3M stock comp and $32.3M unrealized securities losses.","Adjusted EBITDA $(2.8)M, improved from $(16.2)M in Q1 2025.","Raised FY2026 revenue guidance to $1.59-1.60B (~25% annual growth); maintains ~$65M Adj. EBITDA outlook.","MRD test volume ~6,500, up ~500% YoY; expanded collaborations with Merck, Gilead, Northwestern Medicine."],"consensus_eps_estimate":-0.1935,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":348116000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107686,"accession_number":"0001193125-26-066931","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI Q4 revenue $367.2M (+83% YoY); guides FY26 revenue ~$1.59B, adj. EBITDA ~$65M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $367.2M (+83% YoY, 33.5% organic); Diagnostics $266.9M (+121.6%) with Oncology volume +29%, Hereditary +23%.","Data and Apps revenue $100.4M (+25.1%); Insights ex-warrant grew 69.5%; total remaining contract value >$1.1B, NRR 126%.","Q4 net loss $54.2M vs $13.0M loss YoY; Adj. EBITDA improved to $12.9M from ($7.8M) prior year.","FY2025 revenue $1.3B (+83.4%); net loss $245.0M; Adj. EBITDA ($7.4M) vs ($104.7M) prior year.","Cash and marketable securities $759.7M; FY2026 guidance: revenue ~$1.59B, Adj. EBITDA ~$65M."],"consensus_eps_estimate":-0.0422,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":1271789000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107685,"accession_number":"0001193125-26-009650","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI reports preliminary FY2025 revenue ~$1.27B (+83% YoY); TCV exceeds $1.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 revenue ~$1.27B (+83% YoY); diagnostics ~$955M (+111%), data/apps ~$316M (+31%).","Q4 2025 revenue ~$367M (+83% YoY); diagnostics ~$266M (+121%), data/apps ~$100M (+25%).","Record total contract value >$1.1B as of Dec 31, 2025; net revenue retention ~126%.","Signed data agreements with >70 customers including AstraZeneca, Pfizer, Novartis, Merck, Eli Lilly, etc.","Preliminary results subject to change; final earnings call in Feb 2026."],"consensus_eps_estimate":-0.0422,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":1271789000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124052,"accession_number":"0001193125-25-264616","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI Q3 revenue $334M (+84.7% YoY); turns positive adjusted EBITDA; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $334.2M, +84.7% YoY; gross profit $209.9M, +98.4% YoY.","Adjusted EBITDA positive $1.5M vs ($21.8M) loss YoY; net loss ($80.0M) includes $35M stock comp and $12M debt extinguishment loss.","Genomics revenue $252.9M (+117.2% YoY); Data and services $81.3M (+26.1%).","2025 revenue guidance raised to ~$1.265B (~80% growth); Q4 Adj. EBITDA expected ~$20M.","Acquired Paige (AI digital pathology); 217k clinical tests delivered (+33% YoY)."],"consensus_eps_estimate":-0.1695,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":904578000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140730,"accession_number":"0001193125-25-189857","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tempus AI files prospectus supplement for resale of 1,268,033 shares by selling stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement on August 27, 2025, covering resale of 1,268,033 Class A common shares.","Shares registered under automatic shelf registration statement (S-3) filed August 8, 2025.","Legal opinion from Brownstein Hyatt Farber Schreck attached regarding legality of the shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140729,"accession_number":"0000950170-25-105441","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI Q2 rev $315M (+90% YoY); raises FY25 guidance to $1.26B, adj EBITDA $5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $314.6M (+89.6% YoY); genomics up 115% to $241.8M; data/services +35.7% to $72.8M.","Gross profit $195.0M (+158% YoY); net loss improved to ($42.8M) from ($552.2M); adj EBITDA ($5.6M) vs ($31.2M).","Issued $750M 0.75% convertible notes; cash $293M; FY guidance raised: rev ~$1.26B, adj EBITDA $5M.","Oncology testing volume +26% YoY; hereditary +32%; >212,000 NGS tests delivered in Q2."],"consensus_eps_estimate":-0.2449,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":570372000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140728,"accession_number":"0001193125-25-155545","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Tempus AI closes $750M 0.75% convertible note offering, repays $274.7M term loans","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M aggregate principal of 0.75% Convertible Senior Notes due July 15, 2030, including full over-allotment.","Net proceeds ~$721.7M; used $274.7M to repay senior secured term loans and $41.8M for capped call transactions.","Initial conversion price ~$84.19 per share (32.5% premium over $63.54 closing price on June 30, 2025).","Entered capped call transactions to reduce potential dilution, with cap price initially $111.195 per share.","Amended credit agreement to permit offering and satisfy junior capital raise, avoiding 0.50% margin increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158469,"accession_number":"0001193125-25-125425","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tempus AI shareholders approve reincorporation from Delaware to Nevada at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reincorporation approved with 229,810,726 votes for, 13,226,368 against, 44,166 abstentions.","All nine director nominees elected including Eric Lefkofsky, Jennifer Doudna, Scott Gottlieb.","Ratification of PricewaterhouseCoopers as independent auditor for FY2025 ratified (258,785,082 for).","Board retains discretion to abandon the reincorporation; company would remain named Tempus AI, Inc.","Class B stockholders have 30 votes per share vs. 1 vote for Class A; meeting held May 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158468,"accession_number":"0000950170-25-064419","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus Q1 revenue up 75.4% to $255.7M; raises FY2025 revenue guidance to $1.25B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $255.7M (+75.4% YoY); gross profit $155.2M (+99.8% YoY) with margin improvement in Genomics and Data & Services.","Net loss $68.0M (incl. $28.2M stock comp & $31.8M fair value losses); adjusted EBITDA -$16.2M vs -$43.9M YoY.","Collaborations with AstraZeneca and Pathos; $200M in data licensing/model development fees over 3 years.","Full year 2025 revenue guidance raised to ~$1.25B (~80% growth); expects positive adjusted EBITDA of $5M.","Genomics revenue $193.8M (+88.9% YoY); Data & Services revenue $61.9M (+43.2% YoY; Insights up 58%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":255737000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158467,"accession_number":"0001193125-25-090062","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempus AI inks deals with AstraZeneca, Pathos for $200M data licensing, $35M fee for oncology AI model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AstraZeneca pays Tempus $35M under MSA for foundational multimodal oncology model developed by Pathos using Tempus de-identified data.","Tempus and Pathos sign Order Form: Pathos pays $200M data license fees over 3 years ($50M upfront); Tempus receives license to use model.","Pathos may pay up to 50% of data license fees in shares of Pathos Series D Preferred Stock at its discretion.","Tempus pays Pathos $35M in consideration for Pathos' commitments under the Pathos Master Agreement.","Syndicate led by AstraZeneca will execute stock purchase agreement with Pathos in preferred stock financing round."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176840,"accession_number":"0000950170-25-025587","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI Q4 revenue $200.7M (+35.8% YoY); guides FY25 revenue ~$1.24B, Adj. EBITDA ~$5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $200.7M (+35.8% YoY); Genomics $120.4M, Data $80.2M. Gross profit $122.1M (+49.7%).","FY24 revenue $693.4M (+30.4%); net loss $705.8M (incl. $547.7M stock comp); Adj. EBITDA loss $104.7M.","Closed Ambry Genetics acquisition Feb 3, 2025; combined FY25 revenue guidance ~$1.24B (+79% YoY).","Expects FY25 Adj. EBITDA ~$5M (improvement of ~$110M over FY24).","CMS reimbursement for Tempus ECG-AF algorithm at $138/test; xT CDx granted ADLT status with $4,500 reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":693398000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176839,"accession_number":"0001193125-25-019313","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Tempus AI borrows $300M to fund Ambry Genetics acquisition – term loans and revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $200M in incremental term loans and $100M in revolving loans on Feb 3, 2025.","Proceeds used to partly fund the Ambry Genetics acquisition announced Nov 4, 2024.","New term loan and ABL facilities mature Feb 3, 2030; existing term loans mature Sept 2027.","Term loans accrue interest at base rate + 6.25% or SOFR + 7.25% (cash); revolver at base + 2.75% or SOFR + 3.75%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176838,"accession_number":"0001193125-25-005041","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI Q4 2024 revenue ~$200M (+35% YoY); full year ~$693M (+30%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue ~$200M, up ~35% YoY; full-year revenue ~$693M, up ~30%.","Adjusted EBITDA improved sequentially in Q4; company expects ~100% of full-year adjusted EBITDA guidance.","Genomics revenue grew ~30% in Q4; data & services revenue grew ~45%.","Softness in CRO revenues noted; core businesses gained momentum during the year."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":693398000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193643,"accession_number":"0001193125-24-251239","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Tempus AI to acquire Ambry Genetics for $375M cash plus ~4.84M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Ambry Genetics (genetic testing) for $375M cash + 4,843,136 TEM shares valued at ~$46.46/share avg VWAP.","Debt financing from Ares: $200M term loan + $100M revolving credit facility to fund cash consideration and fees.","Expected close in Q1 2025 subject to HSR clearance and other customary conditions.","Seller (Konica Minolta's REALM IDx) provides limited indemnity; Tempus obtained buyside R&W insurance policy.","Lock-up on 2,152,505 shares of stock consideration for one year; registration rights granted for stock consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193642,"accession_number":"0000950170-24-120663","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus AI Q3 revenue $180.9M (+33% YoY), net loss $75.8M, agrees to buy Ambry Genetics for $600M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Q3 revenue $180.9M (+33% YoY); net loss $75.8M (incl. $22.2M stock comp); Adj EBITDA -$21.8M (improved $14.4M YoY).","FY2024 guidance: revenue ~$700M (~32% growth), Adj EBITDA ~($105M), improvement of ~$50M over 2023.","Acquired Ambry Genetics for $600M ($375M cash + $225M shares); Ambry expects >$300M rev, >$40M EBITDA in CY2024.","Data & services rev +64.4% YoY, Insights rev +86.6%; Genomics unit growth 23.9%, rev +20.3%.","Debt financing: $300M increase from Ares; cash & marketable securities $466.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209963,"accession_number":"0001193125-24-215157","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempus AI defers settlement of 4.47M CEO RSUs to Jan-Mar 2025 with sell-to-cover expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee deferred settlement of ~4,469,400 RSUs held by CEO Eric Lefkofsky.","RSUs vested at IPO or during lock-up period ending December 10, 2024.","Deferred settlement period: January 15, 2025 to March 15, 2025.","Company expects sell-to-cover of ~1,915,988 shares for tax withholding (assumed 42% rate)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209962,"accession_number":"0001493152-24-033274","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tempus AI invests $17.7M in Personalis, exercises warrants for 9.2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased 3,500,000 Personalis shares at $5.07/share, aggregate $17,745,000.","Exercised warrants for 9,218,800 shares at $1.50 and $2.50, totaling $18,437,600.","Amended Commercialization Agreement: termination notice extended to 30 months.","New obligations for Personalis in event of assignment or change of control to a Tempus competitor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209961,"accession_number":"0001193125-24-194863","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tempus Q2 revenue $166M, up 25% YoY; guides FY2024 revenue ~$700M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $166.0M (+25% YoY); data licensing grew 40% YoY; genomics revenue $112.3M (+22.2%).","Net loss ($552.2M) largely from $493.1M stock compensation and payroll taxes tied to IPO.","Adjusted EBITDA ($31.2M), improved $12.7M QoQ from Q1; Non-GAAP genomics margin 49.4% (+50bps).","FY2024 revenue guidance ~$700M (~32% growth); adjusted EBITDA guided at ~($105M), improvement of ~$50M.","Launched MRD assays, JV with SoftBank for Japan, FDA 510(k) for ECG-AF device, CMS ADLT status for xT CDx."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":311789000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228149,"accession_number":"0001193125-24-162594","cik":1717115,"company_name":"Tempus AI, Inc.","ticker":"TEM","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tempus AI files amended charter and bylaws effective upon IPO closing on June 17, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of Tempus AI closed on June 17, 2024; shares trade on Nasdaq under 'TEM'.","Amended and restated certificate of incorporation filed with Delaware Secretary of State.","Amended and restated bylaws adopted effective June 17, 2024.","Provisions of charter and bylaws described in final prospectus filed June 17, 2024 (Rule 424(b))."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9219752748.931099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}